M&A Deal Summary |
|
|---|---|
| Date | 2006-02-02 |
| Target | FMS Future Medical System S.A. |
| Sector | Medical Products |
| Buyer(s) | Johnson & Johnson |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1886 |
| Sector | Consumer Products |
| Employees | 132,000 |
| Revenue | 88.8B USD (2024) |
Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 15 of 47 |
| Sector: Medical Products M&A | 9 of 17 |
| Type: Add-on Acquisition M&A Deals | 11 of 39 |
| Country: Switzerland M&A | 1 of 3 |
| Year: 2006 M&A | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-12-16 |
Animas
West Chester, Pennsylvania, United States Animas Corp., an insulin delivery company. Provides insulin delivery products like our OneTouch® Ping™ glucose management system and the inset® family of all-in-one infusion sets, which work with any pump. |
Buy | $518M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-06-26 |
Pfizer Consumer Healthcare
Berlin, Germany Pfizer Consumer Healthcare GmbH global business of personal care and over-the-counter (OTC) products. A leading brands include LISTERINE oral care products and the NICORETTE line of smoking cessation treatments. Other widely recognized and trusted brands include LUBRIDERM, VISINE, NEOSPORIN, SUDAFED, ZANTAC and BENADRYL. |
Buy | $16.6B |
